BR112014005404A2 - citomegalovírus (cmv) defectivo em replicação condicional, composição, métodos para induzir uma resposta imune contra cmv e para preparo de cmv defectivo em replicação condicional, e, uso do cmv defectivo em replicação condicional - Google Patents
citomegalovírus (cmv) defectivo em replicação condicional, composição, métodos para induzir uma resposta imune contra cmv e para preparo de cmv defectivo em replicação condicional, e, uso do cmv defectivo em replicação condicionalInfo
- Publication number
- BR112014005404A2 BR112014005404A2 BR112014005404A BR112014005404A BR112014005404A2 BR 112014005404 A2 BR112014005404 A2 BR 112014005404A2 BR 112014005404 A BR112014005404 A BR 112014005404A BR 112014005404 A BR112014005404 A BR 112014005404A BR 112014005404 A2 BR112014005404 A2 BR 112014005404A2
- Authority
- BR
- Brazil
- Prior art keywords
- cmv
- defective
- conditional replication
- cyvomegalovirus
- inducing
- Prior art date
Links
- 230000002950 deficient Effects 0.000 title 3
- 230000010076 replication Effects 0.000 title 3
- 230000028993 immune response Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/03—Herpetoviridae, e.g. pseudorabies virus
- C07K14/04—Varicella-zoster virus
- C07K14/045—Cytomegalovirus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161532667P | 2011-09-09 | 2011-09-09 | |
PCT/US2012/053599 WO2013036465A2 (en) | 2011-09-09 | 2012-09-04 | A conditional replicating cytomegalovirus as a vaccine for cmv |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014005404A2 true BR112014005404A2 (pt) | 2017-03-28 |
BR112014005404A8 BR112014005404A8 (pt) | 2023-04-11 |
Family
ID=47832753
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014005404A BR112014005404A8 (pt) | 2011-09-09 | 2012-09-04 | Citomegalovírus (cmv) defectivo em replicação condicional, composição, uso da composição, método para preparo de cmv defectivo em replicação condicional, e, uso do cmv defectivo em replicação condicional |
Country Status (33)
Country | Link |
---|---|
US (1) | US9546355B2 (pt) |
EP (3) | EP3251700B1 (pt) |
JP (1) | JP5926804B2 (pt) |
KR (1) | KR101668163B1 (pt) |
CN (1) | CN103889462B (pt) |
AR (1) | AR087772A1 (pt) |
AU (1) | AU2012304783B2 (pt) |
BR (1) | BR112014005404A8 (pt) |
CA (1) | CA2846870C (pt) |
CL (1) | CL2014000541A1 (pt) |
CY (2) | CY1119107T1 (pt) |
DK (2) | DK2753364T3 (pt) |
ES (2) | ES2737852T3 (pt) |
HR (2) | HRP20171120T1 (pt) |
HU (2) | HUE045115T2 (pt) |
IL (1) | IL231272B (pt) |
IN (1) | IN2014CN01809A (pt) |
LT (2) | LT2753364T (pt) |
ME (2) | ME02831B (pt) |
MX (1) | MX353037B (pt) |
NZ (1) | NZ622156A (pt) |
PE (1) | PE20141525A1 (pt) |
PL (2) | PL3251700T3 (pt) |
PT (2) | PT3251700T (pt) |
RS (2) | RS58891B1 (pt) |
RU (2) | RU2611198C2 (pt) |
SG (1) | SG11201400419YA (pt) |
SI (2) | SI3251700T1 (pt) |
TR (1) | TR201910644T4 (pt) |
TW (1) | TWI570240B (pt) |
UA (1) | UA114896C2 (pt) |
WO (1) | WO2013036465A2 (pt) |
ZA (1) | ZA201401708B (pt) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2016501023A (ja) * | 2012-12-04 | 2016-01-18 | メルク・シャープ・アンド・ドーム・コーポレーションM | 条件付き複製ウイルスベクター |
MX2015016978A (es) * | 2013-06-10 | 2016-04-25 | Merck Sharp & Dohme | Proteinas de union a antigeno neutralizantes de citomegalovirus. |
UA120938C2 (uk) | 2014-07-16 | 2020-03-10 | Орегон Хелс Енд Сайєнс Юніверсіті | Цитомегаловірус людини, що містить екзогенний антиген |
EP3048114A1 (en) * | 2015-01-22 | 2016-07-27 | Novartis AG | Cytomegalovirus antigens and uses thereof |
EP3364981A4 (en) | 2015-10-22 | 2019-08-07 | ModernaTX, Inc. | VACCINE AGAINST THE HUMAN CYTOMEGALOVIRUS |
US10611800B2 (en) | 2016-03-11 | 2020-04-07 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
US11446398B2 (en) | 2016-04-11 | 2022-09-20 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
JP6980780B2 (ja) | 2016-10-21 | 2021-12-15 | モデルナティーエックス, インコーポレイテッド | ヒトサイトメガロウイルスワクチン |
CA3079828A1 (en) * | 2017-11-01 | 2019-05-09 | Merck Sharp & Dohme Corp. | Stable formulations of cytomegalovirus |
US20210047626A1 (en) * | 2018-04-24 | 2021-02-18 | Merck Sharp & Dohme Corp. | Scalable chromatography process for purification of human cytomegalovirus |
US11629172B2 (en) | 2018-12-21 | 2023-04-18 | Pfizer Inc. | Human cytomegalovirus gB polypeptide |
WO2020142304A1 (en) | 2019-01-03 | 2020-07-09 | Merck Sharp & Dohme Corp. | Supplemented serum-containing culture medium for enhanced arpe-19 growth and human cytomegalovirus vaccine production |
EP3997107A1 (en) * | 2019-07-12 | 2022-05-18 | Københavns Universitet | Fusion toxin proteins for treatment of diseases related to cmv infections |
TWI810589B (zh) | 2020-06-21 | 2023-08-01 | 美商輝瑞股份有限公司 | 人巨細胞病毒糖蛋白B(gB)多肽 |
US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
CN112481222B (zh) * | 2020-11-30 | 2024-01-02 | 中国医学科学院医学生物学研究所 | 一种条件复制型重组单纯疱疹病毒、疫苗及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1150712B1 (en) * | 1999-02-05 | 2008-11-05 | Merck & Co., Inc. | Human papilloma virus vaccine formulations |
AU2003301148A1 (en) | 2002-12-23 | 2004-07-22 | Vical Incorporated | Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection |
US20060110406A1 (en) * | 2003-02-25 | 2006-05-25 | Medimmune Vaccines, Inc. | Refrigerator-temperature stable influenza vaccine compositions |
US20040228842A1 (en) * | 2003-02-27 | 2004-11-18 | Shan Lu | Compositions and methods for cytomegalovirus treatment |
SG164344A1 (en) * | 2005-02-18 | 2010-09-29 | Novartis Vaccines & Diagnostics Srl | Immunogens from uropathogenic escherichia coli |
CA2654563A1 (en) * | 2006-06-07 | 2007-12-21 | The Trustees Of Princeton University | Cytomegalovirus surface protein complex for use in vaccines and as a drug target |
US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
US9439960B2 (en) * | 2007-10-10 | 2016-09-13 | The Trustees Of Princeton University | Cytomegalovirus vaccines and methods of production |
US8530636B2 (en) * | 2008-05-07 | 2013-09-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells in vivo using synthetic small molecules |
-
2012
- 2012-09-03 TW TW101132064A patent/TWI570240B/zh active
- 2012-09-04 RS RS20190753A patent/RS58891B1/sr unknown
- 2012-09-04 SG SG11201400419YA patent/SG11201400419YA/en unknown
- 2012-09-04 MX MX2014002815A patent/MX353037B/es active IP Right Grant
- 2012-09-04 KR KR1020147008959A patent/KR101668163B1/ko active IP Right Grant
- 2012-09-04 CA CA2846870A patent/CA2846870C/en active Active
- 2012-09-04 PL PL17171651T patent/PL3251700T3/pl unknown
- 2012-09-04 BR BR112014005404A patent/BR112014005404A8/pt not_active Application Discontinuation
- 2012-09-04 DK DK12830346.8T patent/DK2753364T3/en active
- 2012-09-04 WO PCT/US2012/053599 patent/WO2013036465A2/en active Application Filing
- 2012-09-04 PL PL12830346T patent/PL2753364T3/pl unknown
- 2012-09-04 PT PT17171651T patent/PT3251700T/pt unknown
- 2012-09-04 IN IN1809CHN2014 patent/IN2014CN01809A/en unknown
- 2012-09-04 EP EP17171651.7A patent/EP3251700B1/en active Active
- 2012-09-04 ME MEP-2017-157A patent/ME02831B/me unknown
- 2012-09-04 UA UAA201403638A patent/UA114896C2/uk unknown
- 2012-09-04 AR ARP120103253A patent/AR087772A1/es active IP Right Grant
- 2012-09-04 TR TR2019/10644T patent/TR201910644T4/tr unknown
- 2012-09-04 SI SI201231634T patent/SI3251700T1/sl unknown
- 2012-09-04 HU HUE17171651A patent/HUE045115T2/hu unknown
- 2012-09-04 HU HUE12830346A patent/HUE035322T2/en unknown
- 2012-09-04 RU RU2014113921A patent/RU2611198C2/ru active
- 2012-09-04 ES ES17171651T patent/ES2737852T3/es active Active
- 2012-09-04 EP EP12830346.8A patent/EP2753364B1/en active Active
- 2012-09-04 DK DK17171651.7T patent/DK3251700T3/da active
- 2012-09-04 PE PE2014000323A patent/PE20141525A1/es active IP Right Grant
- 2012-09-04 LT LTEP12830346.8T patent/LT2753364T/lt unknown
- 2012-09-04 EP EP19175776.4A patent/EP3572096A1/en active Pending
- 2012-09-04 US US14/343,637 patent/US9546355B2/en active Active
- 2012-09-04 LT LTEP17171651.7T patent/LT3251700T/lt unknown
- 2012-09-04 PT PT128303468T patent/PT2753364T/pt unknown
- 2012-09-04 RS RS20170715A patent/RS56261B1/sr unknown
- 2012-09-04 ME MEP-2019-176A patent/ME03488B/me unknown
- 2012-09-04 AU AU2012304783A patent/AU2012304783B2/en active Active
- 2012-09-04 SI SI201231003T patent/SI2753364T1/sl unknown
- 2012-09-04 JP JP2014529788A patent/JP5926804B2/ja active Active
- 2012-09-04 ES ES12830346.8T patent/ES2633190T3/es active Active
- 2012-09-04 NZ NZ622156A patent/NZ622156A/en unknown
- 2012-09-04 RU RU2017102888A patent/RU2670012C1/ru active
- 2012-09-04 CN CN201280053360.7A patent/CN103889462B/zh active Active
-
2014
- 2014-03-02 IL IL231272A patent/IL231272B/en active IP Right Grant
- 2014-03-06 CL CL2014000541A patent/CL2014000541A1/es unknown
- 2014-03-07 ZA ZA2014/01708A patent/ZA201401708B/en unknown
-
2017
- 2017-07-20 HR HRP20171120TT patent/HRP20171120T1/hr unknown
- 2017-07-20 CY CY20171100780T patent/CY1119107T1/el unknown
-
2019
- 2019-06-18 HR HRP20191111TT patent/HRP20191111T1/hr unknown
- 2019-08-06 CY CY20191100836T patent/CY1121863T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014005404A2 (pt) | citomegalovírus (cmv) defectivo em replicação condicional, composição, métodos para induzir uma resposta imune contra cmv e para preparo de cmv defectivo em replicação condicional, e, uso do cmv defectivo em replicação condicional | |
EP2771490A4 (en) | METHOD AND COMPOSITIONS FOR ASSESSING PATIENTS WITH REPRODUCTIVE DISORDER ON THE BASIS OF MIRNA FROM IMMUNOCELLS | |
BR112017015944A2 (pt) | composições de oligossacarídeo para uso em ração animal e métodos para produzir as mesmas | |
CL2015003440A1 (es) | Composiciones de arni contra tmprss6 y métodos para su uso | |
BR112014020121A2 (pt) | bandeja para uso em uma subarmação de uma armação, métodos para usar uma bandeja e para usar uma subarmação, e, subarmação | |
DK3088353T3 (da) | Bilirubinpartikler og deres fremstilling til anvendelse i terapi | |
BR112014007158A2 (pt) | uso de extrato de albizia julibrissin, composição, e, uso da composição | |
AP2013007242A0 (en) | Composition and method for enhancing an immune response | |
EP2686600A4 (en) | SYSTEM AND METHOD FOR A TILTABLE STAND | |
BR112014001135A2 (pt) | método para formação de imagem de uma região subterrânea, e, sistema para o uso na formação de imagem de uma região subterrânea | |
BR112015010947A2 (pt) | composições e métodos para aumentar o metabolismo energético. | |
DK2744456T3 (da) | Forbedringer ved eller i forbindelse med proteser og ortoser | |
CO6870003A2 (es) | Vacunas bovinas y métodos | |
BR112014010290A2 (pt) | composição farmacêutica, métodos, composições e usos | |
HK1203438A1 (en) | Method and device for fast dissolution of solid protein composition | |
CO6970609A2 (es) | Composición farmacéutica y métodos de uso de derivados de 4-pregenen-11ß-17-21-triol-3,20-diona | |
BR112014016243A8 (pt) | apoio de braço, em particular para uso em cadeiras de escritório | |
BR112013022411A2 (pt) | artigo absorvente e método para preparar um artigo absorvente | |
BR112013018742A2 (pt) | cya-transportador de polipeptídeo(s) e use para induzir tanto as terapias e resposta imunitária profilática | |
IL229381B (en) | Brilacitidine and its results for use in the treatment of mucositis | |
BR112013022883A2 (pt) | aptâmero, composição farmacêutica, kit, uso de um aptâmero e coluna de aférese | |
BR112014000773A2 (pt) | composições de nicotinamida e uso terapêutico das mesmas | |
BR112014010515A2 (pt) | método para controlar uma população de erva daninha em um ambiente, e, composição | |
BR112014013990A2 (pt) | retardador hidrodinâmico desconectável e método para controlar o mesmo | |
CO7010844A2 (es) | Métodos para aislar (4-cloro-2-fluor-3-fenilo-sustituido)boronatos y métodos para su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: MERCK SHARP AND DOHME LLC (US) |